Anatara Lifesciences Ltd (ASX:ANR)

Market Cap	2.84M -72.1%
Revenue (ttm)	623.76K -30.3%
Net Income	-1.31M
EPS	-0.01
Shares Out	315.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,000
Open	0.0090
Previous Close	0.0100
Day's Range	0.0090 - 0.0090
52-Week Range	0.0040 - 0.0200
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 9, 2026

About Anatara Lifesciences

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company’s products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight redu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ANR

Financial Performance

In fiscal year 2025, Anatara Lifesciences's revenue was 969,456, an increase of 50.53% compared to the previous year's 644,026. Losses were -1.95 million, 34.7% more than in 2024.